Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using genetic variation to optimize cancer chemotherapy.

Howard L McLeod1, Chris Papageorgio, James W Watters

  • 1Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110, USA. hmcleod@im.wustl.edu

Clinical Advances in Hematology & Oncology : H&O
|October 15, 2005
PubMed
Summary

Pharmacogenetics uses genetic variations to tailor cancer chemotherapy, addressing unpredictable treatment responses and toxicity. This approach personalizes drug selection for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

JCO precision oncology·2026
Same author

Propranolol metabolite and enantiomers affect colorectal cancer development by inhibiting MAPK pathway and downregulating PD-1 expression.

International immunopharmacology·2025
Same author

A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors.

Cancer letters·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025
Same author

Causal effects of immune cells on the efficacy and adverse drug reactions of platinum drugs.

Acta biochimica et biophysica Sinica·2025
Same author

Pharmacogenomics in Oncology-Running Out of Excuses for Slow Adoption.

JAMA network open·2024

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Genetics

Background:

  • Interpatient variability in chemotherapy response presents a significant clinical challenge.
  • Lack of objective tools for selecting chemotherapy regimens contributes to treatment inefficiencies.
  • Unpredictable efficacy and systemic toxicity are common issues in cancer chemotherapy.

Purpose of the Study:

  • To review recent clinically relevant examples of cancer pharmacogenetics.
  • To explore how genetic differences can personalize cancer chemotherapy.
  • To highlight the role of pharmacogenetics in addressing chemotherapy challenges.

Main Methods:

  • Review of current literature on cancer pharmacogenetics.
  • Analysis of genetic polymorphisms influencing drug metabolism, transport, target, and DNA repair.

Related Experiment Videos

  • Discussion of clinical applications and future directions in individualized cancer therapy.

    • Main Results:

    • Genetic polymorphisms in drug metabolism, transport, target, and DNA repair genes are linked to chemotherapy response variability.
    • Pharmacogenetics offers a pathway to individualize drug treatment for cancer patients.
    • Emerging evidence supports the use of genetic information to optimize chemotherapy regimens.

    Conclusions:

    • Pharmacogenetics is crucial for overcoming interpatient variability in chemotherapy response.
    • Individualized cancer chemotherapy based on genetic profiles promises improved efficacy and reduced toxicity.
    • Genetic insights are reshaping the future of oncology treatment.